Incyte rises as it will present new data on thrombocythemia asset at conference

June 03, 2025 10:33 AM PDT | By EODHD

Google News:

Incyte rises as it will present new data on thrombocythemia asset at conference — Image source: Kalkine Media

Recent News

Kalkine Valens Semiconductor Joins NYSE Composite Amid Rising Sector A...

Kalkine FinVolution Group’s Role in the NYSE Composite Landscape

CoreCard Co. Listed in Russell 1000 Index by Kalkine

S&P 500 Chart with Kalkine Key Trends and Market Movements

[Essential thrombocythemia] Hailshadow/iStock via Getty Images * Incyte (NASDAQ:INCY [https://seekingalpha.com/symbol/INCY]) is up ~3% in Tuesday trading following word it will present late-breaking data on INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody for thrombocythemia at the European Hematology Association Congress later this month. * "We believe the data that will be presented...demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia, and support its potential to be a disease modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia," Incyte President and Head of Research and Development Pablo Cagnoni said in a statement. * Thrombocythemia is a disorder where bone marrow makes too many platelets, causing blood to clot more easily. * At the Congress, Incyte will also be making presentations [https://seekingalpha.com/pr/20124957-incyte-announces-multiple-presentations-including-new-late-breaking-data-for-its-mutcalr] on NCA035784, an equipotent T cell redirecting antibody for myeloproliferative neoplasms; ruxolitinib and anemia-supporting medications to myelofibrosis; and results from a phase 3 trial of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma. MORE ON INCYTE * Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs [https://seekingalpha.com/article/4790883-incyte-good-company-but-potentially-overvalued-given-patent-cliffs] * Incyte Corporation 2025 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4779533-incyte-corporation-2025-q1-results-earnings-call-presentation] * Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4779258-incyte-corporation-incy-q1-2025-earnings-call-transcript] * SA Asks: Which oncology companies are attractive M&A targets? [https://seekingalpha.com/news/4452742-sa-asks-which-oncology-companies-are-attractive-ma-targets] * Incyte gets expanded FDA approval for Zynyz in anal cancer [https://seekingalpha.com/news/4449091-incyte-gets-expanded-fda-approval-for-zynyz-in-anal-cancer]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.